Chemed Inc (CHE) 145.45 $CHE Chemed Tops Q2 Earnings on

New Post Public Reply Private Reply Replies (0) Message Board

Jul 29, 2015 at 12:25 PM

Chemed Inc (CHE) 145.45 $CHE

Chemed Tops Q2 Earnings on Strong Revenues, Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:03AM CDT
Chemed Corp. (CHE) reported second-quarter 2015 adjusted earnings per share (EPS) of $1.66 from continuing operations, outshining the Zacks Consensus Estimate by 9.2%.
CHE: 145.45 (+0.71), ABAX: 48.91 (+0.58), AMED: 44.53 (+0.38), NUVA: 54.42 (+3.95)

Chemed Has Returned 16.8% Since SmarTrend Recommendation (CHE)
Comtex SmarTrend(R) - Mon Jul 27, 9:27AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on May 11th, 2015 at $121.64. In approximately 3 months, Chemed has returned 16.85% as of today's recent price of $142.13.
CHE: 145.45 (+0.71)

Chemed posts 2Q profit
Automated Insights - Thu Jul 23, 4:58PM CDT
CINCINNATI (AP) _ Chemed Corp. (CHE) on Thursday reported second-quarter earnings of $27 million.
CHE: 145.45 (+0.71)

Chemed Reports Second-Quarter 2015 Results
Business Wire - Thu Jul 23, 3:01PM CDT
Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest provider of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2015, versus the comparable prior-year period, as follows:
CHE: 145.45 (+0.71)

Chemed Up 11.4% Since SmarTrend Uptrend Call (CHE)
Comtex SmarTrend(R) - Tue Jul 14, 10:06AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on May 11th, 2015 at $121.64. In approximately 2 months, Chemed has returned 11.35% as of today's recent price of $135.45.
CHE: 145.45 (+0.71)

Chemed To Report Second-Quarter 2015 Earnings July 23, Related Conference Call To Be Held On July 24
Business Wire - Thu Jul 09, 10:30AM CDT
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the second quarter ended June 30, 2015, on Thursday, July 23, 2015, following the close of trading on the New York Stock Exchange.
CHE: 145.45 (+0.71)

Best And Worst: Mid Cap Value ETFs, Mutual Funds And Key Holdings
David Trainer - Seeking Alpha - Wed Jun 24, 8:30AM CDT
The Mid Cap Value style ranks seventh out of the 12 fund styles as detailed in our Q2'15 Style Ratings report . It gets our Dangerous rating, which is based on an aggregation of ratings of 16 ETFs and 166 mutual funds in the Mid Cap Value style. ...
CHE: 145.45 (+0.71), PXMV: 26.59 (+0.23), LNT: 59.77 (-0.77), SYLD: 31.52 (+0.22)

Chemed's Top Line Continues to Grow, Roto-Rooter Holds Key - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 23, 1:25PM CDT
On Jun 22, 2015, we updated our research report on Chemed Corporation (CHE).
CHE: 145.45 (+0.71), AMSG: 69.07 (-0.42), PMC: 34.11 (+0.36), DVA: 79.21 (+0.19)

Amedisys (AMED) Continues to Rally: Add to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 22, 1:50PM CDT
On Jun 22, 2015, we issued an updated research report on Amedisys Inc. (AMED).
CHE: 145.45 (+0.71), AMSG: 69.07 (-0.42), DVA: 79.21 (+0.19), AMED: 44.53 (+0.38)

Dividend Challengers And Near-Challengers: 34 Increases Expected In The Next 11 Weeks
David Fish - at Seeking Alpha - Wed Jun 17, 1:38AM CDT

SAFT: 56.75 (-0.14), TILE: 24.23 (+0.23), HSY: 91.90 (-0.12), BT: 74.08 (+1.09), RGA: 97.10 (+1.05), DEO: 115.18 (+1.80), CHE: 145.45 (+0.71), PAYX: 46.42 (-0.19), CBOE: 60.58 (+0.23), CMI: 128.79 (+0.79), WY: 30.11 (+0.06), WAYN: 12.75 (-0.25), SUSQ: 14.31 (+0.06), CLMS: 12.01 (-0.01), LGCY: 8.95 (-0.18), HAR: 109.23 (+1.71), MRLN: 16.22 (+0.08), BSET: 32.82 (-0.66), RECN: 15.56 (+0.29), LFUS: 92.68 (+1.61), SMG: 60.69 (+0.95), KINS: 7.65 (+0.05), EDR: 31.79 (-0.62), RAS: 5.54 (+0.18), CF: 59.25 (+0.35), MPC: 54.75 (+0.24), CVLY: 20.36 (+0.11), SBGI: 28.20 (+0.05), KLAC: 51.66 (-0.26), MRO: 21.63 (+0.43), BMTC: 29.33 (+0.27), IPHS: 51.98 (+0.66)

Is Chemed's Economic Castle Enough For Investors?
Valuentum - at Seeking Alpha - Thu Jun 11, 8:01AM CDT

CHE: 145.45 (+0.71)

Chemed Corporation to Present at the Jefferies 2015 Global Healthcare Conference
Business Wire - Thu May 28, 7:00AM CDT
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3, 2015, at approximately 2:30 p.m. (ET) in New York City.
CHE: 145.45 (+0.71)

Chemed declares $0.22 dividend
Seeking Alpha - at Seeking Alpha - Mon May 18, 2:16PM CDT

CHE: 145.45 (+0.71)

Chemed Corporation Holds Annual Meeting of Shareholders; Board Declares Quarterly Dividend
Business Wire - Mon May 18, 1:56PM CDT
Shareholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company's 2015 annual shareholders' meeting. Each of the directors continues from the prior term.
CHE: 145.45 (+0.71)

Quest Diagnostics' QNatal Advanced for Prenatal Screening - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 14, 1:30PM CDT
Quest's (DGX) QNatal Advanced is a noninvasive prenatal screening test that detects common as well as rare chromosomal abnormalities in maternal blood.
CHE: 145.45 (+0.71), AMSG: 69.07 (-0.42), DGX: 73.34 (+1.22), AMED: 44.53 (+0.38)

DaVita's Inorganic Growth Impresses, MA Rate Cuts a Concern - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 11, 2:55PM CDT
We issued an updated research report on DaVita HealthCare Partners Inc. (DVA) on May 8, 2015.
CHE: 145.45 (+0.71), AMSG: 69.07 (-0.42), DVA: 79.21 (+0.19), AAC: 39.32 (-0.28)

Chemed Looks Good After Another Earnings Beat
Jonathan Weber - at Seeking Alpha - Mon May 11, 10:22AM CDT

CHE: 145.45 (+0.71)

Chemed Corporation to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
Business Wire - Fri May 08, 10:11AM CDT
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, at 1:40 PM (PDT) at the Encore at the Wynn Las Vegas.
CHE: 145.45 (+0.71)

AmSurg Beats Q1 Earnings on Solid Revenues; Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 07, 12:35PM CDT
AmSurg (AMSG) delivered mixed first-quarter 2015 results beating the Zacks Consensus Estimate for earnings, but missing the mark for revenues.
CHE: 145.45 (+0.71), AMSG: 69.07 (-0.42), DGX: 73.34 (+1.22), AMED: 44.53 (+0.38)

Chemed Corporation to Present at the Deutsche Bank 40th Annual Health Care Conference
Business Wire - Mon May 04, 12:39PM CDT
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015, at approximately 10:40 a.m. (ET) at The InterContinental Hotel in Boston, MA.
CHE: 145.45 (+0.71), DB: 33.40 (+0.16)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...